Remove 2018 Remove Clinical Development Remove Pharmaceuticals
article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.

article thumbnail

PRITELIVIR MESYLATE

New Drug Approvals

Pritelivir (development codes AIC316 or BAY 57-1293 ) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG. 2018 Oct 23;9:2483.

Virus 62
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

Medical researchers and practitioners see in their own patients how these ailments interconnect and overlap, as do the pharmaceutical and biotech companies working to develop GLP-1 therapeutics. It is worth noting that trial ran from 2018 to 2021, before the U.S.

article thumbnail

Macrocyclization via Ring-Closing Metathesis in Drug Discovery & Process Chemistry

Drug Hunter

Recent Applications of Ring-Closing Metathesis in Drug Discovery and Development A selection of representative macrocycles in drug discovery where ring-closing metathesis has been applied to their synthesis are shown below, highlighting chemically diverse macrocycles from programs that have reached clinical development.

article thumbnail

Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

The Pharma Data

01, 2020 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. 333-228656) previously filed with the Securities and Exchange Commission (the “SEC”) on December 3, 2018, and declared effective by the SEC on December 26, 2018. About Allena Pharmaceuticals Allena Pharmaceuticals, Inc. NEWTON, Mass.,

article thumbnail

New avenues for rare disease treatment

Drug Target Review

Small molecules have been the mainstay of the pharmaceutical industry for nearly a century, they are easy to deliver – they are often given orally – and our health systems have a lot of experience of working with them. 2018 [cited 2023 Sep 5]. Autophagy boosters, in contrast, are conventional small molecule drugs. cited 2023 Sep 5].

Disease 113
article thumbnail

Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market

The Pharma Data

02, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘China Grand Pharma’) for Telix’s portfolio of Molecularly-Targeted Radiation (‘MTR’) products. .